Hundreds of biotech startups pop up yearly, and their fate typically has three options. They can flourish into successful independent companies of their own, shrink and shutter in failure, or, most likely, make an exit through a merger or acquisition to a larger company. 

Timothy K. Lu, Co-founder, and CEO of Senti Biosciences, Inc., moderated the panel “Exit Strategies for Early Stage New Drug Companies” at BIO Asia-Taiwan 2022, which began July 27 with the theme of “Connecting the Asian Value Chain.” The event brings together biotechnology, pharmaceutical executives, and investors worldwide to explore business opportunities in Taiwan’s emerging biotech sector. 

During the panel, five respected industry experts provided their thoughts on startup exit strategies and the considerations for maneuvering within the biotech industry. The panelists issued their opinions on the importance of an initial plan when starting a company, the opportunities and limitations of cross-border investments, and sufficient international patent protection in a globalized world.